Piramal bets on pharma's data binging in $635M buyout

Sold on the growing need for market data in biopharma, India's Piramal Healthcare has scooped up Decision Resources Group in deal valued at about $635 million, Piramal and DRG revealed Wednesday. The deal comes amid rapid business expansion at Decision Resources, which provides web-based research tools, predictive analytics and other services to drugmakers and other healthcare stakeholders. An attracive buyout target, Decision Resources has managed to retain 95% of its customers while serving 48 of the 50 top biopharma companies in the world. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.